Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million – STAT

  1. Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million  STAT
  2. Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker  CNBC
  3. What’s Going On With Gene Therapy Company Bluebird Bio Stock Today?  Yahoo Finance
  4. bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital  Business Wire
  5. Bluebird bio to sell to investment funds after struggling to make money from gene therapies  Endpoints News